ICU rounds is a production of the Society of Critical Care Medicine.

This is ICU rounds. My name is Dr. Jeffrey Guy.

I'm an associate professor of surgery and director of the Burns Center at the Vanderbilt University School of Medicine.

Hey everybody, welcome back.

This is Jeff Guy.

Clearly, one of the leading causes of death in the trauma patients, certainly the

leading cause of early death in trauma patients, is that associated with hemorrhage.

And there's been a tremendous amount of effort associated with reducing these early deaths by the

development of pre-hospital trauma care systems, improvement, and EMS education, and EMS delivery

systems, the introduction of tourniquets into the pre-hospital and battlefield environment.

But there's also been some advances in medications that perhaps can be delivered in the way

we transfuse blood

and blood products of patients who are with a life-threatening hemorrhage. What we're going to

discuss today is the role of transamic acid. There is an article recently that looked at several

articles in studies, namely the crash studies,

that looked at transamic acid.

And the idea behind the use of transamic acid is this is a medication that could be administered

in the early period following a traumatic injury, and that this may reduce the rate of ongoing

bleeding and therefore hopefully reduce the early deaths associated

to the anguination as well as some of the complications that develop later perhaps in the days

the weeks to follow due to the effect of hypervalinic shock associated with ongoing bleeding.

So we're going to talk about this study that was called the Crash 2 study.

...